Rybodyn was founded by Imad Ajjawi, Corey Dambacher, Kerry Wilson, Ashley Woodfin.

Who are Rybodyn's investors?

Rybodyn's investors include Phase Two Ventures, SOSV, Swell Partners, HOF Capital.

Rybodyn

4 known investors

Find your way into Rybodyn

Paths you didn't know you had: your email and LinkedIn already hold routes to the Rybodyn team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

RyboDyn develops breakthrough immunotherapies by identifying and targeting previously hidden disease markers through its proprietary RyboCypher™ technology platform. The company serves patients in need of next-generation treatments for diseases associated with cryptic biological targets.

AI & Machine Learning Biotech Deep Tech Healthtech

Founders & leadership

Imad Ajjawi Co-Founder & Chief Executive OfficerImad Ajjawi founded Denovium, an AI-driven protein discovery and design company, which was subsequently acquired by Absci. He is the co-founder and CEO of RyboDyn, which develops immunotherapies using its proprietary RyboCypher™ technology platform.

Corey Dambacher Founder, President, & Chief Technology OfficerDr. Corey Dambacher holds a Ph.D. in chemistry from Scripps Research and has worked on synthetic biology and platform development, including at Omniome prior to its 2021 acquisition. He is the Founder, President, and Chief Technology Officer of RyboDyn, a biotechnology company developing immunotherapies targeting the dark proteome.

Kerry WilsonCo-Founder & VP, Platform Development

Ashley Woodfin Co-Founder & Bioinformatics Lead - Target DiscoveryWith over a decade of experience in computational analysis for sequencing platforms, she has worked on dark RNA sequencing, proteogenomic target discovery, single-cell and epigenomic methods, and functional genomics across immunotherapy and early detection applications, including roles at Scale Biosciences (acquired by 10x Genomics).

Investors · 4

Phase Two Ventureslisted by Phase Two VenturesSan Diego

How we know: Phase Two Ventures's portfolio page · Not right? Tell us

SOSVlisted by SOSVNew York · $30K – $550K

How we know: funding news · open dataset · 5k.vc investor directory · sosv.com · Not right? Tell us

Swell Partnerslisted by Swell PartnersNew York City · $500K – $600K

How we know: Swell Partners's portfolio page · the VCSheet dataset · Not right? Tell us

HOF CapitalreportedNew York · $500K – $10M

How we know: a partner's Signal profile · Not right? Tell us

Frequently asked questions

What does Rybodyn do?: RyboDyn develops breakthrough immunotherapies by identifying and targeting previously hidden disease markers through its proprietary RyboCypher™ technology platform. The company serves patients in need of next-generation treatments for diseases associated with cryptic biological targets.
Who founded Rybodyn?: Rybodyn was founded by Imad Ajjawi, Corey Dambacher, Kerry Wilson, Ashley Woodfin.
Who are Rybodyn's investors?: Rybodyn's investors include Phase Two Ventures, SOSV, Swell Partners, HOF Capital.